

**Final Draft Agenda**  
**46<sup>th</sup> meeting of the Committee for Socio-economic Analysis**

**10-12 March 2020**  
**and**  
**17-19 March 2020**

**ECHA Conference Centre, Sisu meeting room (Telakkakatu 6,  
Helsinki)**

**Tuesday 10 March starts at 14.00**  
**Thursday 12 March breaks at 16.30**  
**Tuesday 17 March resumes at 14.00**  
**Thursday 19 March ends at 16.30**

**Item 1 – Welcome and Apologies**

**Item 2 – Adoption of the Agenda**

***SEAC/A/46/2019***  
***For adoption***

**Item 3 – Declarations of conflicts of interest to the Agenda**

**Item 4 – Report from other ECHA bodies and activities**

- a) Report on SEAC-45 action points, written procedures and update on other ECHA bodies

***For information***

**Item 5 – Restrictions**

**5.1 General restriction issues**

- a) Report from the Restrictions Task Force

- b) Revision of the RAC and SEAC working procedure on opinion development

**SEAC/46/2020/01**

**For information**

## **5.2 Restriction Annex XV dossiers**

- a) Conformity and key issues discussion

- 1) Undecafluorohexanoic acid (PFHxA), its salts and related substances

**For agreement**

- b) Opinion development

- 1) Calcium cyanamide in fertilisers – second draft opinion

**For discussion**

- 2) Skin sensitisers in textile – fourth draft opinion

- 3) Microplastics – fifth draft opinion

- 4) Perfluorohexane-1-sulphonic acid, its salts and related substances – fourth draft opinion

- 5) Formaldehyde and formaldehyde releasers – fourth draft opinion

- 6) Five cobalt salts – fifth draft opinion

**For discussion and agreement**

- 7) Siloxanes (D4, D5 and D6) – draft final opinion

**For discussion and adoption**

## **5.3 Appointment of (co-)rapporteurs for restriction dossiers**

**For information**

### **Item 6 – Authorisation**

#### **6.1 General authorisation issues**

- a) Update on incoming/future applications

- b) Report from the Commission Workshop on AfAs (3 February 2020)

**For information**

#### **6.2 Authorisation applications**

- a) Discussion on key issues

- 1) 11 applications for authorisation from November 2019 submission window (OPE/NPE)

**For discussion**

- b) Agreement on draft opinion

- 1) 147\_CTPht\_Bilbaina (1 use)

- 2) 148\_CTPht\_DEZA (1 use)
- 3) 155\_OPE\_Siemens\_2 (5 uses)
- 4) 156\_OPE\_Hospira (1 use)
- 5) 160\_OPE\_Merck\_2 (1 use)
- 6) 162\_OPE\_LFB (1 use)
- 7) 163\_OPE\_Rentschler (1 use)
- 8) 174\_OPE\_Eli\_Lilly (1 use)
- 9) 175\_OPE\_Rousselot (1 use)
- 10)180\_OPE\_NPE\_Bio-Rad (4 uses)
- 11)186\_OPE\_NPE\_Beckman (5 uses)
- 12)187\_OPE\_AGC (2 uses)
- 13)189\_OPE\_Lonza (1 use)
- 14)190\_OPE\_TEVA (1 use)
- 15)191\_NPE\_Sekisui (1 use)

***For discussion and agreement***

- c) Adoption of opinion
- 1) CT\_TES (1 use)
  - 2) OPE\_Boehringer (1 use)

***For discussion and adoption***

- d) Status update
- 1) AfAs agreed at SEAC-45
  - 2) 165\_OPE\_bioMerieux\_2 (1 use)
  - 3) 170\_OPE\_DiaSorin (1 use)
  - 4) 172\_OPE\_DIAGAST (1 use)
  - 5) 176\_OPE\_Abbott\_1 (5 uses)
  - 6) 182\_NPE\_Abbott (1 use)
  - 7) 184\_OPE\_Lilly (1 use)
  - 8) 185\_OPE\_NPE\_Idexx (3 uses)

***For information***

### **6.3 Appointment of (co-)rapporteurs for authorisation applications**

***SEAC/46/2020/02  
(restricted room document)  
For agreement***

#### **Item 7 – AOB**

- a) Update of the work plan

***For information***

#### **Item 8 – Action points and main conclusions of SEAC-46**

Table with Conclusions and Action points from SEAC-46

***For adoption***